June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
The Effects of Pediatric Primary Brain Tumors on Vision and Quality of Life
Author Affiliations & Notes
  • Jason Peragallo
    Emory University, Atlanta, GA
  • Supharat Jariyakosol
    Emory University, Atlanta, GA
    Chulalongkorn University, Bangkok, Thailand
  • Beau B Bruce
    Emory University, Atlanta, GA
  • Nancy J. Newman
    Emory University, Atlanta, GA
  • Valerie Biousse
    Emory University, Atlanta, GA
  • Footnotes
    Commercial Relationships Jason Peragallo, None; Supharat Jariyakosol, None; Beau Bruce, None; Nancy Newman, None; Valerie Biousse, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5206. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jason Peragallo, Supharat Jariyakosol, Beau B Bruce, Nancy J. Newman, Valerie Biousse; The Effects of Pediatric Primary Brain Tumors on Vision and Quality of Life. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5206.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Brain tumors are the leading cause of death from childhood cancer. Improvements in detection, therapy, and surveillance have improved survival. Permanent sequelae of the tumor and its treatment may cause severe impairment and reduced quality of life (QOL). We reviewed the literature and initiated a quality improvement (QI) project evaluating visual impairment and its effects on QOL.


Patients ≤18 yo & ≥6 months post primary brain tumor (PBT) diagnosis, excluding primary intrinsic anterior visual pathway tumors, underwent neuro-ophthalmologic examination. In the QI project, patients and parents completed Health-related QOL (HR-QOL) [PedsQL Brain Tumor Module] and Vision-related QOL (VR-QOL) questionnaires [children <8yo: Children’s Visual Function Questionnaire; 8-18yo: EYE-Q]. Demographic data, driving status, schooling, and use of low-vision aids were recorded. Patients were classified as normal, visually impaired, or legally blind. We reviewed recent studies (2000-2014) of ophthalmologic sequelae, long-term disability, and QOL in pediatric PBT patients.


32 PBT patients were evaluated (24 supra-, 8 infra-tentorial). 3/32 (9.3%) were legally blind; 15/32(46.9%) had visual impairment; 15/31(48.4%) had significant visual field defects, 16/32(50%) had strabismus, cranial nerve palsies, or nystagmus. Patients' median HR-QOL was 68.6 (range 28.1-95.8). Parents’ HR-QOL scores for their children were 0.82x (SE±0.25) their children's score(R2=0.59;p<0.001). VR-QOL median score was 3.35 (range 0.38-4.0). HR-QOL scores were not significantly correlated with visual function. EYE-Q was -3.0 points lower (SE±0.64;p<0.001) in those with severe visual impairment vs. those with none. Twelve studies met our criteria for review. Prevalence of visual dysfunction ranged from 8-79%. 3/12 studies reported frequency of bilateral blindness (3-16%). HR-QOL was significantly lower in PBT patients compared to normal controls in most studies. VR-QOL was not addressed in recent pediatric PBT studies.


Children with PBT and their parents have similar perceptions of HR-QOL. VR-QOL loss was associated with visual dysfunction in PBT patients in our center’s experience. "Cured" pediatric PBT patients may have severely affected vision, HR-QOL, and VR-QOL. Systematic neuro-ophthalmologic examinations of pediatric PBT patients may improve long-term visual outcomes and QOL through earlier intervention.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.